Research activities focus on cancer immunology, developmental biology, biotechnology, and translational medicine.

Current work is centered on the development of a synthetic cancer vaccine platform inspired by earlier investigations into developmental and tumor-associated antigens and supported by modern recombinant biotechnology approaches.

Research

The project builds upon earlier studies of embryonic and tumor-associated antigens and explores how these concepts can be translated into a modern biotechnology framework.

Rather than relying on biologically derived materials, the platform explores the use of recombinant technologies to improve reproducibility, manufacturing consistency, and future translational potential.

The long-term objective is to improve understanding of developmental and tumor-associated antigens and to support future research in cancer immunology, translational oncology, and biotechnology.

Cancer Immunology

Research into developmental and tumor-associated antigens as potential targets for immune recognition and cancer prevention. This work formed the basis of earlier anti-cancer immunotherapy concepts and continues to influence current research activities.

Antigen Discovery

Identification and characterization of developmental, embryonic, and tumor-associated antigens as potential targets for immunological and oncology research.

Recombinant Biotechnology

Application of recombinant expression systems, molecular biology, and protein engineering technologies for the development of recombinant antigen systems and related biomedical applications

Vaccine Development

Investigation of standardized and scalable approaches for the design, production, and evaluation of recombinant and subunit vaccine candidates.

Translational Oncology

Development of approaches intended to translate laboratory discoveries in immunology and biotechnology into practical biomedical applications, with a particular focus on cancer prevention and immunotherapy.

Potential Impact

This research explores a standardized approach to the generation and evaluation of defined tumor-associated antigens using recombinant and synthetic technologies.

By combining concepts from developmental biology, cancer immunology, and biotechnology, the project seeks to provide a reproducible framework for studying immune responses to tumor-associated targets and supporting future research in translational oncology.